Please login to the form below

Not currently logged in


This page shows the latest leukaemia news and features for those working in and with pharma, biotech and healthcare.

CAR-Ts take centre stage as ASH18 comes to a close

CAR-Ts take centre stage as ASH18 comes to a close

Among the highlights, Allogene and partner Servier presented phase 1 data for its ‘off-the-shelf’ CAR-T therapy UCART19 in acute lymphoblastic leukaemia (ALL), making the case for an easier ... relapsed or refractory (r/r) acute lymphoblastic

Latest news

More from news
Approximately 70 fully matching, plus 342 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    AstraZeneca. Anti-NKG2A antibody (monalizumab), IPH5201 (antibody targeting CD38) and Lumoxiti. #. for hairy cell leukaemia. Development &. commercialisation. collaboration. $307m. ViraTherapeutics/. Boehringer Ingelheim. ... Manufacture and supply of

  • Biopharma's Future: Made in China Biopharma's Future: Made in China

    Novartis’ leukaemia treatment Glivec.

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    The field is marching on rapidly. Studies of checkpoint inhibitors are now taking place in less common forms of cancer with greater unmet needs, such as gastric cancer, acute myelocytic leukaemia ... antigen receptor T-cell (CAR-T) therapies from

  • No incentive for a cure No incentive for a cure

    These include Kymriah, the pioneering CAR-T cell therapy from Novartis, which demonstrated a remarkable 83% remission rate in children and young adults with B-cell precursor acute lymphoblastic leukaemia.

  • Deal Watch January 2018

    lymphoblastic leukaemia (ALL), Juno's share price had been in the low $20s for several months.  The company switched focus to its JCAR017 programme and recently reported promising data in a

More from intelligence
Approximately 1 fully matching, plus 43 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...